Table 2.

Participants with emergent IAS-USA darunavir mutations

Participants	IAS-USA darunavir mutations											Other IAS-USA PI mutations	Previous PI (n)	Subtype	Time to DRMb (months)	ART with darunavir
	11I	32I	33F	47V	50V	54M	54L	74P	76V	84V	89V
1	▪											36I, 60E, 69K, 89M, 93L	0	C	1.2	RAL
2	▪											10I, 20I, 36I, 69K, 89M	0	K	2.1	ABC/3TC
3		▪										10I, 36I, 62V, 77I, 93L	0	B	5.8	TDF/FTC
4									▪			10F, 20R, 36I, 46I, 54V, 69K, 71V, 82A, 89M, 93L	0	C	10.0	TDF/FTC
5	▪											62V, 63P, 77I, 93L	1	B	7.3	FTC/TDF
6			□							▪	□	10V, 36L, 48V, 54S, 58E, 62V, 63P, 71I, 73S, 82A, 90M	4a	B	9.2	T20/TDF
7		▪	□							□		10I, 20R, 36I, 48V, 54S, 62V, 63P, 64V, 71V, 82A, 93M	5a	B	11.4	T20/NVP/FTC/TDF
8		□	▪	□			□			□	□	10F, 20R, 36I, 36L, 46I, 62V, 63P, 71T, 90M, 93L	3a	B	4.5	ETR/TDF
9							▪		▪			36I, 46I, 63P, 69K, 82I, 89M, 93L	2a	C	26.6	FTC/TDF
10		▪	▪						▪	□		10I, 20T, 36I, 46I, 54V, 58E, 63P, 69K, 82L, 89M	6a	G	2.8	ddI/TDF
11	▪	▪	□				▪	□		□		10I, 36L, 43T, 46L, 54V, 58E, 63P, 82T, 89I	5	B	0.4c	T20/ETR/3TC/TDF

RAL, raltegravir; ABC, abacavir; 3TC, lamivudine; TDF, tenofovir; FTC, emtricitabine; T20, enfuvirtide; NVP, nevirapine; ETR, etravirine; ddI, didanosine; ▪, emergent mutation; □, baseline mutation.

^aParticipant received another PI for <90 days following baseline test.

^bTime from start of darunavir to post-exposure genotype with emergent darunavir DRM.

^c32I detected at 0.4 months, 11I and 54L detected at 9 months.